Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Silence Therapeutics (SLN) Operating Leases (2023 - 2025)

Silence Therapeutics (SLN) has disclosed Operating Leases for 2 consecutive years, with $71000.0 as the latest value for Q4 2025.

  • Quarterly Operating Leases changed N/A to $71000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $71000.0 through Dec 2025, changed N/A year-over-year, with the annual reading at $71000.0 for FY2025, N/A changed from the prior year.
  • Operating Leases hit $71000.0 in Q4 2025 for Silence Therapeutics, down from $97000.0 in the prior quarter.
  • In the past five years, Operating Leases ranged from a high of $115427.1 in Q4 2023 to a low of $71000.0 in Q4 2025.